Securian Asset Management Inc. Sells 4,761 Shares of Elevance Health, Inc. $ELV

Securian Asset Management Inc. cut its position in shares of Elevance Health, Inc. (NYSE:ELV) by 44.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,043 shares of the company’s stock after selling 4,761 shares during the period. Securian Asset Management Inc.’s holdings in Elevance Health were worth $2,118,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ELV. Physician Wealth Advisors Inc. boosted its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares during the last quarter. Activest Wealth Management boosted its position in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the last quarter. Rossby Financial LCC boosted its position in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the last quarter. ORG Partners LLC boosted its position in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Elevance Health during the 4th quarter valued at approximately $38,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

NYSE:ELV opened at $381.58 on Tuesday. The firm has a market capitalization of $82.86 billion, a price-to-earnings ratio of 16.23, a PEG ratio of 2.15 and a beta of 0.66. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $424.24. The business has a 50 day simple moving average of $315.03 and a 200-day simple moving average of $332.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the prior year, the business posted $11.97 earnings per share. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ELV shares. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Citigroup upgraded Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Leerink Partners set a $364.00 target price on Elevance Health in a research report on Thursday, April 23rd. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Finally, Weiss Ratings raised Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Thirteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.